SuperworthQuoin Pharmaceuticals EPS QNRX
Diluted earnings per share by quarter and over the last twelve months, from 2022.
- Last 12 months, to Jun 30, 2026
- −$12.12
- Latest quarter, Q2 FY26
- −$1.90
- Fiscal year 2025
- −$21.23
Quoin Pharmaceuticals' earnings per share was −$12.12 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.90.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$21.23 | n/a |
| FY2024 | −$81.70 | n/a |
| FY2023 | −$10.25 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.90 | n/a | −$12.12 | |
| Q1 FY26 | −$1.77 | n/a | −$16.50 | |
| Q4 FY25 | −$1.74 | n/a | −$21.23 | |
| Q3 FY25 | −$6.71 | n/a | −$32.49 | |
| Q2 FY25 | −$6.28 | n/a | −$42.07 | |
| Q1 FY25 | −$6.50 | n/a | −$49.47 | |
| Q4 FY24 | −$13.00 | n/a | −$81.70 | |
| Q3 FY24 | −$16.29 | n/a | −$70.78 | |
| Q2 FY24 | −$13.68 | n/a | −$56.44 | |
| Q1 FY24 | −$38.73 | n/a | −$44.89 | |
| Q4 FY23 | −$2.08 | n/a | −$10.25 | |
| Q3 FY23 | −$1.95 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Quoin Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| QNRXQuoin Pharmaceuticals | −$12.12 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Quoin Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.